Skip to main content
Erschienen in: Virchows Archiv 2/2006

01.08.2006 | Original Article

Nonhypotensive dose of β-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure

verfasst von: Kerstin Amann, Jürgen Hofstetter, Valentina Câmpean, Andreas Koch, Marie-Luise Gross, Roland Veelken, Eberhard Ritz

Erschienen in: Virchows Archiv | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

Renal failure causes sympathetic overactivity and inadequate capillary growth in response to cardiomyocyte hypertrophy in experimental renal failure, as well as in uremic patients. In nonuremic animals, sympathetic overactivity was shown to suppress capillary growth. The purpose of this study was to examine whether blockade with α- and β-adrenoblockers ameliorates the capillary deficit that was documented in the hearts of rats with moderate renal failure. Male Sprague–Dawley rats, 3 days after surgical ablation [subtotal nephrectomy (SNX)] or sham operation (sham), were treated with phenoxybenzamine, metoprolol, or a combination of both: After 12 weeks, the hearts were investigated using morphometric and stereologic techniques. The length density of myocardial capillaries was lower (p<0.05) in untreated SNX than in sham (2,786±372 vs 3,397±602 mm/mm3); the decrease was abrogated by metoprolol (3,305±624 mm/mm3), but not by phenoxybenzamin (2,628±480 mm/mm3). The intercapillary distance increased (p<0.05) in SNX (20.5±1.5 μm) and tended to be lower after metoprolol treatment (19.0±1.9 μm). The media area of intramyocardial arterioles was significantly higher in untreated SNX (1,158±1,343 vs 686±771 μm2 in sham). Metoprolol in nonhypotensive doses prevents the capillary deficit in the hearts of rats with moderate renal failure and presents an argument for an important role of sympathetic overactivity in the genesis of the capillary deficit in moderate chronic renal insufficiency.
Literatur
1.
Zurück zum Zitat Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL (2004) Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 164:2465–2471PubMedCrossRef Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL (2004) Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 164:2465–2471PubMedCrossRef
2.
Zurück zum Zitat Agarwal R (1999) Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 55:1528–1535PubMedCrossRef Agarwal R (1999) Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 55:1528–1535PubMedCrossRef
3.
4.
Zurück zum Zitat Amann K, Ritz E, Wiest G, Klaus G, Mall G (1994) A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814–1819PubMed Amann K, Ritz E, Wiest G, Klaus G, Mall G (1994) A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814–1819PubMed
5.
Zurück zum Zitat Amann K, Gharehbaghi H, Stephen S, Mall G (1995) Hypertrophy and hyperplasia of smooth muscle cells of small intramyocardial arteries in spontaneously hypertensive rats. Hypertension 25:124–131PubMed Amann K, Gharehbaghi H, Stephen S, Mall G (1995) Hypertrophy and hyperplasia of smooth muscle cells of small intramyocardial arteries in spontaneously hypertensive rats. Hypertension 25:124–131PubMed
6.
Zurück zum Zitat Amann K, Breitbach M, Ritz E, Mall G (1998) Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9:1018–1022PubMed Amann K, Breitbach M, Ritz E, Mall G (1998) Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9:1018–1022PubMed
7.
Zurück zum Zitat Amann K, Buzello M, Simonaviciene A, Miltenberger-Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E (2000) Capillary/myocyte mismatch in the heart in renal failure—a role for erythropoietin? Nephrol Dial Transplant 15:964–969PubMedCrossRef Amann K, Buzello M, Simonaviciene A, Miltenberger-Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E (2000) Capillary/myocyte mismatch in the heart in renal failure—a role for erythropoietin? Nephrol Dial Transplant 15:964–969PubMedCrossRef
8.
Zurück zum Zitat Amann K, Münter K, Wessels S, Wagner J, Balajew V, Hergenröder S, Mall G, Ritz E (2000) Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 11:1702–1711PubMed Amann K, Münter K, Wessels S, Wagner J, Balajew V, Hergenröder S, Mall G, Ritz E (2000) Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 11:1702–1711PubMed
9.
Zurück zum Zitat Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E (2000) Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11:1469–1478PubMed Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E (2000) Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11:1469–1478PubMed
10.
Zurück zum Zitat Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, Ritz E (2001) Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 60:1309–1323PubMedCrossRef Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, Ritz E (2001) Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 60:1309–1323PubMedCrossRef
11.
Zurück zum Zitat Amann K, Miltenberger-Miltenyi G, Simonoviciene A, Koch A, Orth S, Ritz E (2001) Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade. J Am Soc Nephrol 12:2040–2050PubMed Amann K, Miltenberger-Miltenyi G, Simonoviciene A, Koch A, Orth S, Ritz E (2001) Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade. J Am Soc Nephrol 12:2040–2050PubMed
12.
Zurück zum Zitat Amann K, Veelken R (2003) Mechanisms and consequences of sympathetic hyperactivity in renal disease. Clin Nephrol 60(Suppl 1):S81–S92PubMed Amann K, Veelken R (2003) Mechanisms and consequences of sympathetic hyperactivity in renal disease. Clin Nephrol 60(Suppl 1):S81–S92PubMed
13.
Zurück zum Zitat Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590PubMedCrossRef Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590PubMedCrossRef
14.
Zurück zum Zitat Bragg JL, Mason NA, Maroni BJ, Held PJ, Young EW (2001) Beta-adrenergic antagonist utilization among hemodialysis patients. J Am Soc Nephrol 12:321A Bragg JL, Mason NA, Maroni BJ, Held PJ, Young EW (2001) Beta-adrenergic antagonist utilization among hemodialysis patients. J Am Soc Nephrol 12:321A
15.
Zurück zum Zitat Campean V, Haas CS, Acker T, Ritz E, Plate KH, Amann K (2003) The role of angiogenic factors in the genesis of maladaptation of capillary growth in uremia. J Am Soc Nephrol 14:208ACrossRef Campean V, Haas CS, Acker T, Ritz E, Plate KH, Amann K (2003) The role of angiogenic factors in the genesis of maladaptation of capillary growth in uremia. J Am Soc Nephrol 14:208ACrossRef
16.
Zurück zum Zitat Campese VM (2000) Neurogenic factors and hypertension in renal disease. Kidney Int Suppl 75:S2–S6PubMedCrossRef Campese VM (2000) Neurogenic factors and hypertension in renal disease. Kidney Int Suppl 75:S2–S6PubMedCrossRef
17.
Zurück zum Zitat Campese VM, Kogosov E (1995) Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878–882PubMed Campese VM, Kogosov E (1995) Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878–882PubMed
18.
Zurück zum Zitat Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R (2003) Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438–1444PubMedCrossRef Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R (2003) Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438–1444PubMedCrossRef
19.
Zurück zum Zitat Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912–1918PubMedCrossRef Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912–1918PubMedCrossRef
20.
Zurück zum Zitat Dhein S, Rohnert P, Markau S, Kotchi-Kotchi E, Becker K, Poller U, Osten B, Brodde OE (2000) Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Coll Cardiol 36:608–617PubMedCrossRef Dhein S, Rohnert P, Markau S, Kotchi-Kotchi E, Becker K, Poller U, Osten B, Brodde OE (2000) Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Coll Cardiol 36:608–617PubMedCrossRef
21.
Zurück zum Zitat Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010–2019PubMedCrossRef Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010–2019PubMedCrossRef
22.
Zurück zum Zitat Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16–S23PubMedCrossRef Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16–S23PubMedCrossRef
23.
Zurück zum Zitat Foley RN, Herzog CA, Collins AJ (2002) Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62:1784–1790PubMedCrossRef Foley RN, Herzog CA, Collins AJ (2002) Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62:1784–1790PubMedCrossRef
24.
Zurück zum Zitat Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974–1979PubMedCrossRef Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974–1979PubMedCrossRef
25.
Zurück zum Zitat Hoang D, Macarthur H, Gardner A, Westfall TC (2002) Endothelin-induced modulation of neuropeptide Y and norepinephrine release from the rat mesenteric bed. Am J Physiol Heart Circ Physiol 283:H1523–H1530PubMed Hoang D, Macarthur H, Gardner A, Westfall TC (2002) Endothelin-induced modulation of neuropeptide Y and norepinephrine release from the rat mesenteric bed. Am J Physiol Heart Circ Physiol 283:H1523–H1530PubMed
26.
Zurück zum Zitat Ieda M, Fukuda K, Hisaka Y, Kimura K, Kawaguchi H, Fujita J, Shimoda K, Takeshita E, Okano H, Kurihara Y, Kurihara H, Ishida J, Fukamizu A, Federoff HJ, Ogawa S (2004) Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. J Clin Invest 113:876–884PubMed Ieda M, Fukuda K, Hisaka Y, Kimura K, Kawaguchi H, Fujita J, Shimoda K, Takeshita E, Okano H, Kurihara Y, Kurihara H, Ishida J, Fukamizu A, Federoff HJ, Ogawa S (2004) Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. J Clin Invest 113:876–884PubMed
27.
Zurück zum Zitat Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ (2001) Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12:2427–2433PubMed Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ (2001) Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12:2427–2433PubMed
28.
Zurück zum Zitat Koch M, Thomas B, Tschope W, Ritz E (1993) Survival and predictors of death in dialysed diabetic patients. Diabetologia 36:1113–1117PubMedCrossRef Koch M, Thomas B, Tschope W, Ritz E (1993) Survival and predictors of death in dialysed diabetic patients. Diabetologia 36:1113–1117PubMedCrossRef
29.
Zurück zum Zitat Koomans HA, Blankestijn PJ, Joles JA (2004) Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 15:524–537PubMedCrossRef Koomans HA, Blankestijn PJ, Joles JA (2004) Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 15:524–537PubMedCrossRef
30.
Zurück zum Zitat Leineweber K, Heinroth-Hoffmann I, Ponicke K, Abraham G, Osten B, Brodde OE (2002) Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol 13:117–124PubMed Leineweber K, Heinroth-Hoffmann I, Ponicke K, Abraham G, Osten B, Brodde OE (2002) Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol 13:117–124PubMed
31.
Zurück zum Zitat Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA (1999) Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321–1328PubMedCrossRef Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA (1999) Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321–1328PubMedCrossRef
32.
Zurück zum Zitat Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E (1988) Myocardial interstitial fibrosis in experimental uremia—implications for cardiac compliance. Kidney Int 33:804–811PubMedCrossRef Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E (1988) Myocardial interstitial fibrosis in experimental uremia—implications for cardiac compliance. Kidney Int 33:804–811PubMedCrossRef
33.
Zurück zum Zitat Mann JF, Jakobs KH, Riedel J, Ritz E (1986) Reduced chronotropic responsiveness of the heart in experimental uremia. Am J Physiol 250:H846–H852PubMed Mann JF, Jakobs KH, Riedel J, Ritz E (1986) Reduced chronotropic responsiveness of the heart in experimental uremia. Am J Physiol 250:H846–H852PubMed
34.
Zurück zum Zitat Mattfeld T, Mall G, Gharebhaghi H, Möller P (1990) Estimation of surface area and length with the orientator. J Microsc 159:301–317 Mattfeld T, Mall G, Gharebhaghi H, Möller P (1990) Estimation of surface area and length with the orientator. J Microsc 159:301–317
35.
Zurück zum Zitat Nabokov AV, Amann K, Wessels S, Münter K, Wagner J, Ritz E (1999) Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 55:512–519PubMedCrossRef Nabokov AV, Amann K, Wessels S, Münter K, Wagner J, Ritz E (1999) Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 55:512–519PubMedCrossRef
36.
Zurück zum Zitat Nakamura K, Sasaki S, Moriguchi J, Morimoto S, Miki S, Kawa T, Itoh H, Nakata T, Takeda K, Nakagawa M (1999) Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SP. J Cardiovasc Pharmacol 33:876–882PubMedCrossRef Nakamura K, Sasaki S, Moriguchi J, Morimoto S, Miki S, Kawa T, Itoh H, Nakata T, Takeda K, Nakagawa M (1999) Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SP. J Cardiovasc Pharmacol 33:876–882PubMedCrossRef
37.
Zurück zum Zitat Oberhauser V, Vonend O, Rump LC (1999) Neuropeptide Y and ATP interact to control renovascular resistance in the rat. J Am Soc Nephrol 10:1179–1185PubMed Oberhauser V, Vonend O, Rump LC (1999) Neuropeptide Y and ATP interact to control renovascular resistance in the rat. J Am Soc Nephrol 10:1179–1185PubMed
38.
Zurück zum Zitat Rambausek M, Ritz E, Mall G, Mehls O, Katus H (1985) Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 28:775–782PubMedCrossRef Rambausek M, Ritz E, Mall G, Mehls O, Katus H (1985) Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 28:775–782PubMedCrossRef
39.
Zurück zum Zitat Rascher W, Schömig A, Kreye VA, Ritz E (1982) Diminished vascular response to noradrenaline in experimental chronic uremia. Kidney Int 21:20–27PubMedCrossRef Rascher W, Schömig A, Kreye VA, Ritz E (1982) Diminished vascular response to noradrenaline in experimental chronic uremia. Kidney Int 21:20–27PubMedCrossRef
40.
Zurück zum Zitat Tomanek RJ (1989) Sympathetic nerves modify mitochondrial and capillary growth in normotensive and hypertensive rats. J Mol Cell Cardiol 21:755–764PubMedCrossRef Tomanek RJ (1989) Sympathetic nerves modify mitochondrial and capillary growth in normotensive and hypertensive rats. J Mol Cell Cardiol 21:755–764PubMedCrossRef
41.
Zurück zum Zitat Tomanek RJ, Carlson DW, Palmer PJ, Bhatnagar RK (1987) Role of sympathetic nerves during developing cardiac hypertrophy in Grollman hypertensive rats. Am J Physiol 253:H818–H825PubMed Tomanek RJ, Carlson DW, Palmer PJ, Bhatnagar RK (1987) Role of sympathetic nerves during developing cardiac hypertrophy in Grollman hypertensive rats. Am J Physiol 253:H818–H825PubMed
42.
Zurück zum Zitat Tonello C, Giordano A, Cozzi V, Cinti S, Stock MJ, Carruba MO, Nisoli E (1999) Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats. FEBS Lett 442:167–172PubMedCrossRef Tonello C, Giordano A, Cozzi V, Cinti S, Stock MJ, Carruba MO, Nisoli E (1999) Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats. FEBS Lett 442:167–172PubMedCrossRef
43.
Zurück zum Zitat Törnig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G (1996) Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7:667–675PubMed Törnig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G (1996) Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7:667–675PubMed
44.
Zurück zum Zitat Torry RJ, Connell PM, O’Brien DM, Chilian WM, Tomanek RJ (1991) Sympathectomy stimulates capillary but not precapillary growth in hypertrophic hearts. Am J Physiol 260:H1515–H1521PubMed Torry RJ, Connell PM, O’Brien DM, Chilian WM, Tomanek RJ (1991) Sympathectomy stimulates capillary but not precapillary growth in hypertrophic hearts. Am J Physiol 260:H1515–H1521PubMed
45.
Zurück zum Zitat Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248PubMedCrossRef Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248PubMedCrossRef
46.
Zurück zum Zitat Ye S, Zhong H, Yanamadala V, Campese VM (2002) Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15:717–724PubMedCrossRef Ye S, Zhong H, Yanamadala V, Campese VM (2002) Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15:717–724PubMedCrossRef
47.
Zurück zum Zitat Zuanetti G, Maggioni AP, Keane W, Ritz E (1997) Nephrologists neglect administration of beta blockers to dialysed diabetic patients. Nephrol Dial Transplant 12:2497–2500PubMedCrossRef Zuanetti G, Maggioni AP, Keane W, Ritz E (1997) Nephrologists neglect administration of beta blockers to dialysed diabetic patients. Nephrol Dial Transplant 12:2497–2500PubMedCrossRef
Metadaten
Titel
Nonhypotensive dose of β-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure
verfasst von
Kerstin Amann
Jürgen Hofstetter
Valentina Câmpean
Andreas Koch
Marie-Luise Gross
Roland Veelken
Eberhard Ritz
Publikationsdatum
01.08.2006
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 2/2006
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-006-0219-0

Weitere Artikel der Ausgabe 2/2006

Virchows Archiv 2/2006 Zur Ausgabe

Announcements

Announcements

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …